PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor Mitochondria
Target: BNIP3/BNIP3L
Composite Score: 0.529
Price: $0.53▲8.0%
Citation Quality: Pending
neurodegeneration
Status: proposed
🟢 Parkinson's Disease 🔮 Lysosomal / Autophagy 🔥 Neuroinflammation 🔴 Alzheimer's Disease 🟡 ALS / Motor Neuron Disease 🧠 Neurodegeneration
✓ All Quality Gates Passed
Evidence Strength
Pending (0%)
8
Citations
3
Debates
3
Supporting
3
Opposing
Quality Report Card click to collapse
C+
Composite: 0.529
Top 70% of 1512 hypotheses
T5 Contested
Contradicted by evidence, under dispute
B
0.60
Top 59%
C+
0.50
Top 64%
B+
0.70
Top 45%
C+
0.50
Top 64%
B
0.60
Top 64%
B
0.60
Top 45%
C
0.40
Top 83%
B
0.60
Top 62%
C+
0.50
Top 71%
C+
0.50
Top 66%
Evidence
3 supporting
|
3 opposing
Citation quality: 85%
Debates
1 session
A
Avg quality: 0.81
Convergence
1.00
A+
30 related hypothesis share this target
From Analysis:
Mitochondrial transfer between neurons and glia
What are the mechanisms underlying mitochondrial transfer between neurons and glia?
Description
Inhibition of alternative mitophagy pathways (BNIP3/NIX) in healthy donor cells prevents degradation of transferable mitochondria while maintaining quality control in recipient neurons.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
graph TD
A["Astrocytes / MSCs"] --> B["Healthy Mitochondria Pool"]
B --> C["BNIP3/NIX-Mediated Mitophagy"]
C --> D["Mitochondria Degraded"]
D --> E["Reduced Donor Pool"]
F["PINK1/Parkin-Independent Mitophagy Bypass"] --> G["Selective BNIP3/NIX Inhibition"]
G --> H["Block Alternative Mitophagy in Donors"]
H --> I["Healthy Mito Accumulate"]
I --> J["Enlarged Transferable Mito Pool"]
J --> K["Tunneling Nanotubes"]
J --> L["Extracellular Vesicles"]
K --> M["Mitochondria Delivery to Neurons"]
L --> M
N["Damaged Neurons"] --> O["Bioenergetic Crisis"]
O --> P["ATP Depletion"]
O --> Q["Excessive ROS"]
M --> R["Healthy Mito Integrate into Neurons"]
R --> S["Restored ATP Production"]
R --> T["Normalized ROS Levels"]
R --> U["Ca2+ Homeostasis Recovery"]
S --> V["Neuronal Rescue"]
T --> V
U --> V
V --> W["Neuroprotection Without Parkin Dependency"]
style A fill:#1a3a4a,stroke:#4fc3f7,color:#e0e0e0
style F fill:#264653,stroke:#ffd54f,color:#e0e0e0
style M fill:#1a3a2a,stroke:#81c784,color:#e0e0e0
style W fill:#2a3a1a,stroke:#c5e1a5,color:#e0e0e0
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations
6 with PMID
Validation: 85%
3 supporting / 3 opposing
✓
For
(3)
(3)
Against
✗
High
Medium
Low
High
Medium
Low
Evidence Matrix
— sortable by strength/year, click Abstract to expand
Evidence Types
MECH 6CLIN 0GENE 0EPID 0
Legacy Card View — expandable citation cards
✓ Supporting Evidence 3
PINK1/Parkin-independent mitophagy pathways regulate mitochondrial turnover
Selective mitophagy inhibition enhances mitochondrial transfer efficiency
BNIP3/NIX inhibition preserves healthy mitochondria during stress
✗ Opposing Evidence 3
BNIP3/NIX inhibition leads to accumulation of dysfunctional mitochondria and increased oxidative stress
Neurodegeneration often involves insufficient rather than excessive mitophagy
Mitochondrial transfer efficiency depends more on recipient cell capacity than donor mitochondrial quantity
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 5 rounds | 2026-04-01 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼
Novel Therapeutic Hypotheses for Mitochondrial Transfer in Neurodegeneration
Hypothesis 1: Astrocytic Connexin-43 Upregulation Enhances Neuroprotective Mitochondrial Donation
Description: Pharmacological enhancement of connexin-43 expression in astrocytes increases tunneling nanotube formation and mitochondrial transfer to damaged neurons. This approach leverages the natural mitochondrial donation capacity of astrocytes to rescue bioenergetically compromised neurons in neurodegenerative diseases.
Target: Connexin-43 (GJA1 gene)
Supporting Evidence: Astrocytes transfer func
🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼
Critical Evaluation of Mitochondrial Transfer Hypotheses
Hypothesis 1: Astrocytic Connexin-43 Upregulation
Specific Weaknesses:
- Confounded mechanism: Connexin-43 primarily forms gap junctions for small molecule exchange, not structural tunneling nanotubes for organelle transfer
- Oversimplified pathway: The evidence conflates gap junction communication with physical mitochondrial transfer mechanisms
- Limited therapeutic window: Connexin-43 upregulation could cause seizures and cardiac arrhythmias due to excessive gap junction coupling
Counter-Evidence:
- Connexin
🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼
Practical Feasibility Assessment of Mitochondrial Transfer Hypotheses
Executive Summary
After critical analysis, most hypotheses face significant technical and commercial barriers. Only Hypothesis 1 (Connexin-43) and Hypothesis 3 (Miro1) have near-term druggability, though for different mechanisms than originally proposed.
Hypothesis 1: Astrocytic Connexin-43 Upregulation
Revised Mechanism: Enhanced gap junction-mediated metabolic coupling rather than direct mitochondrial transferDruggability Assessment: MODERATE
Target: Connexin-43 (GJA1) - established⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼
Price History
7d Trend
↘
Falling
7d Momentum
▼ 20.1%
Volatility
Medium
0.0408
Events (7d)
7
⚡ Price Movement Log
Recent 15 events
| Event | Price | Change | Source | Time | |
|---|---|---|---|---|---|
| ⚖ | Recalibrated | $0.529 | ▲ 20.2% | calibrate_stale_price_his | 2026-04-26 13:47 |
| 📄 | New Evidence | $0.440 | ▲ 1.3% | evidence_batch_update | 2026-04-13 02:18 |
| 📄 | New Evidence | $0.434 | ▲ 3.9% | evidence_batch_update | 2026-04-13 02:18 |
| ⚖ | Recalibrated | $0.418 | 2026-04-10 15:58 | ||
| ⚖ | Recalibrated | $0.417 | ▲ 0.3% | 2026-04-08 18:39 | |
| ⚖ | Recalibrated | $0.416 | ▼ 0.8% | 2026-04-04 16:38 | |
| ⚖ | Recalibrated | $0.419 | ▼ 1.5% | 2026-04-04 16:02 | |
| 📄 | New Evidence | $0.426 | ▲ 1.9% | evidence_batch_update | 2026-04-04 09:08 |
| ⚖ | Recalibrated | $0.418 | ▼ 19.2% | 2026-04-03 23:46 | |
| 💬 | Debate Round | $0.517 | ▲ 0.6% | market_dynamics | 2026-04-03 09:21 |
| 📊 | Score Update | $0.514 | ▲ 41.5% | market_dynamics | 2026-04-03 06:59 |
| 💬 | Debate Round | $0.363 | ▼ 35.4% | market_dynamics | 2026-04-03 03:28 |
| 📄 | New Evidence | $0.562 | ▲ 12.0% | market_dynamics | 2026-04-03 03:04 |
| 📄 | New Evidence | $0.502 | ▲ 5.1% | market_dynamics | 2026-04-03 02:42 |
| 💬 | Debate Round | $0.478 | ▼ 8.9% | market_dynamics | 2026-04-03 01:17 |
Clinical Trials (4) Relevance: 13%
2
Active
Active
0
Completed
Completed
0
Total Enrolled
Total Enrolled
Phase I
Highest Phase
Highest Phase
Recruiting
·
NCT04998357
MSC Transplantation for ALS
Phase II
Active
·
NCT03384433
Planning
·
NCT05152394
Mitochondrial Function Biomarkers in Neurodegeneration
Observational
Recruiting
·
NCT04681943
📚 Cited Papers (22)
Transmission dynamics of a linear vanA-plasmid during a nosocomial multiclonal outbreak of vancomycin-resistant enterococci in a non-endemic area, Japan.
Scientific reports (2021) · PMID:34285270
8 figures
Figure 1
Minimum inhibitory concentration of vancomycin and teicoplanin for vancomycin-resistant Enterococcus faecium isolates during the outbreak. According to the criteria of the Clinic...
pmc_api
Figure 2
Dendrogram of pulsotypes in pulsed-field gel electrophoresis and sequence types in multilocus sequence typing among vancomycin-resistant Enterococcus faecium isolates (n = 153). ...
pmc_api
High resolution spatiotemporal patterns of seawater temperatures across the Belize Mesoamerican Barrier Reef.
Scientific data (2020) · PMID:33199700
3 figures
Fig. 1
Map of logger deployment sites in Belize.
pmc_api
Fig. 2
Cross-sectional view of Carrie Bow Caye describing back reef and the two fore reefs in this area: inner fore reef and outer fore reef.
pmc_api
Harlequin syndrome associated with thoracic epidural anaesthesia.
Anaesthesia reports (2022) · PMID:35118419
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
Muscle functions as a connective tissue and source of extracellular matrix in planarians.
Nature communications (2019) · PMID:30962434
No extracted figures yet
Vector competence is strongly affected by a small deletion or point mutations in bluetongue virus.
Parasites & vectors (2020) · PMID:31604476
No extracted figures yet
Extremely Efficient Photocurrent Generation in Carbon Nanotube Photodiodes Enabled by a Strong Axial Electric Field.
Nano letters (2020) · PMID:31847521
No extracted figures yet
An intramembrane chaperone complex facilitates membrane protein biogenesis.
Nature (2020) · PMID:32814900
No extracted figures yet
Association of class number, cumulative exposure, and earlier initiation of antibiotics during the first two-years of life with subsequent childhood obesity.
Metabolism: clinical and experimental (2021) · PMID:32891674
No extracted figures yet
High resolution spatiotemporal patterns of seawater temperatures across the Belize Mesoamerican Barrier Reef.
Scientific data (2020) · PMID:33199700
No extracted figures yet
Anaesthesia and analgesia for knee joint arthroplasty.
BJA education (2018) · PMID:33456789
No extracted figures yet
Transmission dynamics of a linear vanA-plasmid during a nosocomial multiclonal outbreak of vancomycin-resistant enterococci in a non-endemic area, Japan.
Scientific reports (2021) · PMID:34285270
No extracted figures yet
Managing risky assets - mitophagy in vivo.
Journal of cell science (2021) · PMID:34612485
No extracted figures yet
📙 Related Wiki Pages (15)
NURR1 Agonist Therapy for Parkinson's Disease therapeuticNon-Motor Symptoms Treatment in Parkinson's Diseas therapeuticNAD+ Precursors (NMN/NR) for Parkinson's Disease therapeuticMitochondrial Dynamics Modulators for Neurodegener therapeuticNeurorestore Therapies for Parkinson's Disease therapeuticMitochondrial Therapeutics therapeuticMitochondrial Support Strategies for CBS/PSP therapeuticNeurturin (NRTN) Therapy for Parkinson's Disease therapeuticFER Gene geneNSF Gene geneMitochondrial Biogenesis Inducers therapeuticNSF Protein proteinIcaritin GPER Mitophagy for Parkinson's Disease therapeuticDietary Interventions for Parkinson's Disease therapeuticPINK1 Activators for Parkinson's Disease terapeutic
📓 Linked Notebooks (7)
📓 Top 5 Analysis: Sda 2026 04 01 Gap 20260401231108
Computational notebook for SDA-2026-04-01-gap-20260401231108
📓 SciDEX Analysis: 2026 04 01 Gap 20260401231108
Computational notebook for SDA-2026-04-01-gap-20260401231108
📓 Mitochondrial transfer between neurons and glia — Analysis Notebook
Jupyter notebook for analysis SDA-2026-04-01-gap-20260401231108: What are the mechanisms underlying mitochondrial transfer between neurons and glia?
📓 Mitochondrial transfer between neurons and glia — Rich Analysis Notebook
Comprehensive analysis with gene expression, pathway enrichment, and statistical tests for Mitochondrial transfer between neurons and glia
📓 Mitochondrial transfer between neurons and glia — Analysis Notebook
Jupyter notebook for analysis SDA-2026-04-01-gap-20260401231108: What are the mechanisms underlying mitochondrial transfer between neurons and glia?
📓 Mitochondrial transfer between neurons and glia
Analysis ID: SDA-2026-04-01-gap-20260401231108
📓 Mitochondrial transfer between neurons and glia
Analysis ID: SDA-2026-04-01-gap-20260401231108
Date: 2026-04-02
Domain: neurodegeneration
Hypotheses Generated: 7
Knowledge Graph Edges: 0
📊 Resource Economics & ROI
Moderate Efficiency
Resource Efficiency Score
0.71
43.9th percentile (760 hypotheses)
Tokens Used
5,460
KG Edges Generated
7
Citations Produced
8
Cost Ratios
Cost per KG Edge
80.29 tokens
Lower is better (baseline: 2000)
Cost per Citation
546.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
9750.00 tokens
Tokens / composite_score
Score Impact
Efficiency Boost to Composite
+0.071
10% weight of efficiency score
Adjusted Composite
0.600
How Economics Pricing Works
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Efficiency Price Signals
| Date | Signal Price | Score |
|---|---|---|
| 2026-04-16T20:00 | $0.432 | 0.510 |
Wiki Pages
NURR1 Agonist Therapy for Parkinson's DiseasetherapeuticNon-Motor Symptoms Treatment in Parkinson's DiseastherapeuticNAD+ Precursors (NMN/NR) for Parkinson's DiseasetherapeuticMitochondrial Dynamics Modulators for NeurodegenertherapeuticNeurorestore Therapies for Parkinson's DiseasetherapeuticMitochondrial TherapeuticstherapeuticMitochondrial Support Strategies for CBS/PSPtherapeuticNeurturin (NRTN) Therapy for Parkinson's DiseasetherapeuticFER GenegeneNSF GenegeneMitochondrial Biogenesis InducerstherapeuticNSF ProteinproteinIcaritin GPER Mitophagy for Parkinson's DiseasetherapeuticDietary Interventions for Parkinson's DiseasetherapeuticPINK1 Activators for Parkinson's Diseaseterapeutic
Related Hypotheses
CYP46A1 Inhibition Therapy for Neurodegeneration
Score: 0.000 | neurodegeneration
Focused Ultrasound-Enhanced CYP46A1 Gene Therapy for Neurodegeneration
Score: 0.000 | neurodegeneration
Transcranial Magnetic Stimulation-Induced Nanoparticle Delivery via Neuronal Activity Modulation
Score: 0.000 | neurodegeneration
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration
Score: 0.990 | neurodegeneration
CYP46A1 Overexpression Gene Therapy
Score: 0.950 | neurodegeneration
Estimated Development
Estimated Cost
$0
Timeline
2.0 years
🧪 Falsifiable Predictions (5)
5 total
0 confirmed
0 falsified
If hypothesis is true, intervention otherwise be ideal candidates for intercellular transfer
pending
conf: 0.50
Expected outcome: otherwise be ideal candidates for intercellular transfer
Falsified by: Intervention fails to otherwise be ideal candidates for intercellular transfer
If hypothesis is true, intervention quantify transfer efficiency using mitochondrial-targeted fluorescent proteins and live-cell imaging
pending
conf: 0.50
Expected outcome: quantify transfer efficiency using mitochondrial-targeted fluorescent proteins and live-cell imaging
Falsified by: Intervention fails to quantify transfer efficiency using mitochondrial-targeted fluorescent proteins and live-cell imaging
If hypothesis is true, intervention be optimized for different donor cell types, with particular attention to maintaining cell viability and stemness properties in MSCs
pending
conf: 0.50
Expected outcome: be optimized for different donor cell types, with particular attention to maintaining cell viability and stemness properties in MSCs
Falsified by: Intervention fails to be optimized for different donor cell types, with particular attention to maintaining cell viability and stemness properties in MSCs
If hypothesis is true, intervention be stereotactically injected into the substantia nigra to support dopaminergic neurons
pending
conf: 0.50
Expected outcome: be stereotactically injected into the substantia nigra to support dopaminergic neurons
Falsified by: Intervention fails to be stereotactically injected into the substantia nigra to support dopaminergic neurons
If hypothesis is true, intervention provide mitochondrial support to motor neurons
pending
conf: 0.50
Expected outcome: provide mitochondrial support to motor neurons
Falsified by: Intervention fails to provide mitochondrial support to motor neurons
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬 BNIP3 — PDB 2KA2 Click to expand 3D viewer
Source Analysis
Mitochondrial transfer between neurons and glia
neurodegeneration | 2026-04-01 | completed
Community Feedback
0
0 upvotes · 0 downvotes
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
Same Analysis (5)
Astrocytic Connexin-43 Upregulation Enhances Neuroprotective Mitochond
Score: 0.56 · GJA1
Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy
Score: 0.55 · RHOT1
Synthetic Biology Approach: Designer Mitochondrial Export Systems
Score: 0.51 · Synthetic fusion proteins
Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitoc
Score: 0.48 · RAB27A/LAMP2B
Optogenetic Control of Mitochondrial Transfer Networks
→ View all analysis hypotheses
Score: 0.48 · ChR2